Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC).

被引：0
|
作者：
Apolo, Andrea Borghese
Lee, Young H.
Cecchi, Fabiola
Agarwal, Piyush K.
Parnes, Howard L.
Khadar, Kattie
Summerell, Amelia
Gulley, James L.
Compton, Kathryn
Figg, William Douglas
Dahut, William L.
Bottaro, Donald P.
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA
[3] NCI, Canc Prevent Div, Bethesda, MD 20892 USA
[4] NCI, Med Oncol Branch, Bethesda, MD 20892 USA
[5] NCI, Mol Pharmacol Sect, NIH, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4543
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preclinical and correlative studies of cabozantinib (XL184) in urothelial cancer (UC)
    Apolo, Andrea Borghese
    Lee, Young H.
    Cecchi, Fabiola
    Agarwal, Piyush K.
    Parnes, Howard L.
    Khadar, Kattie
    Summerell, Amelia
    Gulley, James L.
    Compton, Kathryn
    Figg, William Douglas
    Dahut, William L.
    Bottaro, Donald P.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [2] Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models
    Sameni, Mansoureh
    Tovar, Elizabeth A.
    Essenburg, Curt J.
    Chalasani, Anita
    Linklater, Erik S.
    Borgman, Andrew
    Cherba, David M.
    Anbalagan, Arulselvi
    Winn, Mary E.
    Graveel, Carrie R.
    Sloane, Bonnie F.
    CLINICAL CANCER RESEARCH, 2016, 22 (04) : 923 - 934
  • [3] XL184 (cabozantinib) for medullary thyroid carcinoma
    Durante, Cosimo
    Russo, Diego
    Verrienti, Antonella
    Filetti, Sebastiano
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (03) : 407 - 413
  • [4] A phase II study of cabozantinib (XL184) in patients with advanced/metastatic urothelial carcinoma
    Apolo, Andrea Borghese
    Parnes, Howard L.
    Madan, Ravi Amrit
    Gulley, James L.
    Wright, John Joseph
    Khadar, Kattie
    Trepel, Jane B.
    Schlom, Jeffrey
    Arlen, Philip M.
    Merino, Maria
    Steinberg, Seth M.
    Choyke, Peter L.
    Lindenberg, Maria Liza
    Kurdziel, Karen A.
    Folio, Les
    Figg, William Douglas
    Agarwal, Piyush K.
    Bottaro, Donald P.
    Dahut, William L.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] A phase I study of cabozantinib (XL184) in patients with renal cell cancer
    Choueiri, T. K.
    Pal, S. K.
    McDermott, D. F.
    Morrissey, S.
    Ferguson, K. C.
    Holland, J.
    Kaelin, W. G.
    Dutcher, J. P.
    ANNALS OF ONCOLOGY, 2014, 25 (08) : 1603 - 1608
  • [6] A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer
    Cabanillas, Maria E.
    Brose, Marcia S.
    Holland, Jaymes
    Ferguson, Kimberly C.
    Sherman, Steven I.
    THYROID, 2014, 24 (10) : 1508 - 1514
  • [7] SENSITIVITY OF GLIOBLASTOMA NEUROSPHERES AND ORTHOTOPIC XENOGRAFTS TO CABOZANTINIB (XL184)
    deCarvalho, Ana C.
    Irtenkauf, Susan
    Hasselbach, Laura
    Xin, Hong
    Mikkelsen, Tom
    NEURO-ONCOLOGY, 2012, 14 : 31 - 31
  • [8] A phase I trial of cabozantinib (XL184) and gemcitabine in advanced pancreatic cancer.
    Zhen, David Bing
    Griffith, Kent A.
    Ruch, Joshua Michael
    Morgan, Meredith
    Kim, Edward Jae-hoon
    Sahai, Vaibhav
    Simeone, Diane M.
    Zalupski, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [9] Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer
    Viola, David
    Cappagli, Virginia
    Elisei, Rossella
    FUTURE ONCOLOGY, 2013, 9 (08) : 1083 - 1092
  • [10] Cabozantinib (XL184) inhibits growth of prostate cancer in the bone and results in an altered bone environment
    Nguyen, Holly M.
    Brown, Lisha G.
    Gross, Ted S.
    Vessella, Robert L.
    Schimmiller, Frauke
    Corey, Eva
    CANCER RESEARCH, 2012, 72
12345